In fact, the TGF-β/SMAD1/S1PR2 pathway is recurrently inactivated in DLBCL due to either disabling mutations in its axis or FOXP1-mediated downregulation [114,115,116]. Here, S1PR2 is linked to diffuse large B-cell lymphoma.